MedTrace Logo

Adjuvant Intravitreal Bevacizumab in Pars Plana Vitrectomy for Vitreous Hemorrhage

NCT01091896 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2010-03-24

No results posted yet for this study

Summary

The purpose of this study is to determine the effect of pre and intra-operative bevacizumab injection on postoperative vitreous hemorrhage after diabetic vitrectomy in comparison to vitrectomy without bevacizumab injection.

Conditions

  • Vitreous Hemorrhage Secondary to PDR

Interventions

DRUG

Bevacizumab

1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy

DRUG

bevacizumab

1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy

Sponsors & Collaborators

  • University of Sao Paulo

    lead OTHER

Principal Investigators

  • Felipe Almeida, MD · University of Sao Paulo

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-09-30
Completion
2011-03-31

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01091896 on ClinicalTrials.gov